191 related articles for article (PubMed ID: 25992239)
21. Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma.
Chen H; Takahara M; Oba J; Xie L; Chiba T; Takeuchi S; Tu Y; Nakahara T; Uchi H; Moroi Y; Furue M
J Dermatol Sci; 2011 Oct; 64(1):39-44. PubMed ID: 21767935
[TBL] [Abstract][Full Text] [Related]
22. Effects of the IL6 -174G>C promoter polymorphism and IL-6 serum levels on the progression of cutaneous malignant melanoma.
Vlaykova T; Kurzawski M; Tacheva T; Dimov D; Anastasov A; Vlaykova D; Miteva A; O'donoghue N; Drozdzik M
Oncol Lett; 2020 Aug; 20(2):1781-1791. PubMed ID: 32724421
[TBL] [Abstract][Full Text] [Related]
23. Metastatic tumor dormancy in cutaneous melanoma: does surgery induce escape?
Tseng WW; Fadaki N; Leong SP
Cancers (Basel); 2011 Feb; 3(1):730-46. PubMed ID: 24212638
[TBL] [Abstract][Full Text] [Related]
24. Incidence of invasive cancers following cutaneous malignant melanoma.
Levi F; La Vecchia C; Randimbison L; Te VC; Erler G
Int J Cancer; 1997 Sep; 72(5):776-9. PubMed ID: 9311593
[TBL] [Abstract][Full Text] [Related]
25. Prognostic risk factors of first recurrence in patients with primary stages I-II cutaneous malignant melanoma - from the population-based Swedish melanoma register.
Lyth J; Falk M; Maroti M; Eriksson H; Ingvar C
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1468-1474. PubMed ID: 28419674
[TBL] [Abstract][Full Text] [Related]
26. Prognostic instrument for survival outcome in melanoma patients: based on data from the population-based Swedish Melanoma Register.
Lyth J; Mikiver R; Nielsen K; Isaksson K; Ingvar C
Eur J Cancer; 2016 May; 59():171-178. PubMed ID: 27046697
[TBL] [Abstract][Full Text] [Related]
27. GSTO1 regards as a meritorious regulator in cutaneous malignant melanoma cells.
Wang LK; Yue HL; Peng XJ; Zhang SJ
Mol Cell Probes; 2019 Dec; 48():101449. PubMed ID: 31525447
[TBL] [Abstract][Full Text] [Related]
28. Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma.
Wei Q; Lee JE; Gershenwald JE; Ross MI; Mansfield PF; Strom SS; Wang LE; Guo Z; Qiao Y; Amos CI; Spitz MR; Duvic M
J Natl Cancer Inst; 2003 Feb; 95(4):308-15. PubMed ID: 12591987
[TBL] [Abstract][Full Text] [Related]
29. Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune.
van den Hurk K; Niessen HE; Veeck J; van den Oord JJ; van Steensel MA; Zur Hausen A; van Engeland M; Winnepenninckx VJ
Biochim Biophys Acta; 2012 Aug; 1826(1):89-102. PubMed ID: 22503822
[TBL] [Abstract][Full Text] [Related]
30. Stage-specific direct health care costs in patients with cutaneous malignant melanoma.
Lyth J; Carstensen J; Synnerstad I; Lindholm C
J Eur Acad Dermatol Venereol; 2016 May; 30(5):789-93. PubMed ID: 25807966
[TBL] [Abstract][Full Text] [Related]
31. Reduced disease-specific survival following a diagnosis of multiple primary cutaneous malignant melanomas-a nationwide, population-based study.
Utjés D; Lyth J; Lapins J; Eriksson H
Int J Cancer; 2017 Dec; 141(11):2243-2252. PubMed ID: 28799271
[TBL] [Abstract][Full Text] [Related]
32. miR-4262 promotes the proliferation of human cutaneous malignant melanoma cells through KLF6-mediated EGFR inactivation and p21 upregulation.
Zhang D; Li Z; Zhang Y; Tu C; Huo J; Liu Y
Oncol Rep; 2016 Dec; 36(6):3657-3663. PubMed ID: 27779691
[TBL] [Abstract][Full Text] [Related]
33. Expression analysis of ovostatin 2 reveals its involvement in proliferation, invasion and angiogenesis of cutaneous malignant melanoma.
Huang YX; Qi J; Wang HS; Shao XB; Zeng XS; Li AM; Xu XL; Sun JF
J Dermatol; 2013 Nov; 40(11):901-10. PubMed ID: 24112097
[TBL] [Abstract][Full Text] [Related]
34. Radioguided sentinel lymph node biopsy in malignant cutaneous melanoma.
Mariani G; Gipponi M; Moresco L; Villa G; Bartolomei M; Mazzarol G; Bagnara MC; Romanini A; Cafiero F; Paganelli G; Strauss HW
J Nucl Med; 2002 Jun; 43(6):811-27. PubMed ID: 12050328
[TBL] [Abstract][Full Text] [Related]
35. Acral Lentiginous Melanoma: Incidence and Survival in the United States, 2006-2015, an Analysis of the SEER Registry.
Huang K; Fan J; Misra S
J Surg Res; 2020 Jul; 251():329-339. PubMed ID: 32208196
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden.
Simberg-Danell C; Lyth J; Månsson-Brahme E; Frohm-Nilsson M; Carstensen J; Hansson J; Eriksson H
Int J Cancer; 2016 Aug; 139(3):543-53. PubMed ID: 27004457
[TBL] [Abstract][Full Text] [Related]
37. Malignant melanomas on head/neck and foot: differences in time and latitudinal trends in Norway.
Juzeniene A; Micu E; Porojnicu AC; Moan J
J Eur Acad Dermatol Venereol; 2012 Jul; 26(7):821-7. PubMed ID: 21707773
[TBL] [Abstract][Full Text] [Related]
38. Risk of second primary malignancies following a diagnosis of cutaneous malignant melanoma or nonmelanoma skin cancer in Alberta, Canada from 1979 to 2009.
Jung GW; Dover DC; Salopek TG
Br J Dermatol; 2014 Jan; 170(1):136-43. PubMed ID: 24443913
[TBL] [Abstract][Full Text] [Related]
39. Correlation among metallothionein expression, intratumoural macrophage infiltration and the risk of metastasis in human cutaneous malignant melanoma.
Emri E; Egervari K; Varvolgyi T; Rozsa D; Miko E; Dezso B; Veres I; Mehes G; Emri G; Remenyik E
J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e320-7. PubMed ID: 22817475
[TBL] [Abstract][Full Text] [Related]
40. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma.
Meier F; Will S; Ellwanger U; Schlagenhauff B; Schittek B; Rassner G; Garbe C
Br J Dermatol; 2002 Jul; 147(1):62-70. PubMed ID: 12100186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
